Symptoms in the context of SARS-CoV-2 vaccination
219 patients experienced any symptom suggestive for an allergic reaction either after the first dose of vaccination (n=214) or after the second dose of vaccination (n=5). 162 experienced immediate symptoms in line with a possible allergic reaction and 55 patients showed other adverse reactions or delayed reactions (maculopapular rash n=12, large local reaction at injection site n=8).
Skin symptoms occurred in the majority of the patients (n=91). The most frequent cutaneous symptom was angioedema (n=45), followed by generalized urticaria (n=36) and generalized erythema/flush (n=20). 70 patients had cardiovascular symptoms; respiratory symptoms were also frequent (n=45) with dyspnea reported in 45 patients. Gastrointestinal symptoms were recorded in 14 patients only. The majority of the symptoms occurred within less than one hour after vaccination, however in a few cases the symptoms appeared within 24 hours after vaccination (7 cases with reported symptoms in line with a possible allergic reaction after 24 hours after vaccination and 4 cases with reported symptoms in line with a possible allergic reaction within 6 to 24 hours after vaccination).
In table 2, patients who experienced immediate symptoms in line with a possible allergic reaction after SARS-CoV-2 vaccination (n=162) are summarized according to the Brighton levels [6]. Only 45 patients met the criteria of anaphylaxis according to the Brighton criteria (level 1 corresponds to the highest, levels 2 and 3 to lower degrees of diagnostic certainty).